Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Stankevich

MA04.01 Cemiplimab, a Human Monoclonal Anti-Pd-1, Alone or in Combination With Radiotherapy: Phase 1 NSCLC Expansion Cohorts

Journal of Thoracic Oncology

English

Related publications

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology

English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer

English

Triple Combination Immunotherapy With GVAX, Anti-Pd-1 Monoclonal Antibody, and Agonist Anti-Ox40 Monoclonal Antibody Is Highly Effective Against Murine Intracranial Glioma

English

Expression of LAG-3 and Efficacy of Combination Treatment With Anti-Lag-3 and Anti-Pd-1 Monoclonal Antibodies in Glioblastoma

International Journal of Cancer

Cancer Research

Oncology

2018

English

MA04.02 Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-Pd-1

Journal of Thoracic Oncology

English

Efficacy of Chemotherapy or Chemo-Anti-Pd-1 Combination After Failed Anti-Pd-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Series From Lysa Centers

American Journal of Hematology

Hematology

2018

English

P3.04-25 EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC With PD-L1 <50%

Journal of Thoracic Oncology

English

Can IDO Activity Predict Primary Resistance to Anti-Pd-1 Treatment in NSCLC?

Journal of Translational Medicine

English

P3.04-24 EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC With PD-L1 ≥50%, a Phase 3 Study

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Stankevich

MA04.01 Cemiplimab, a Human Monoclonal Anti-Pd-1, Alone or in Combination With Radiotherapy: Phase 1 NSCLC Expansion Cohorts

Related publications

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Triple Combination Immunotherapy With GVAX, Anti-Pd-1 Monoclonal Antibody, and Agonist Anti-Ox40 Monoclonal Antibody Is Highly Effective Against Murine Intracranial Glioma

Expression of LAG-3 and Efficacy of Combination Treatment With Anti-Lag-3 and Anti-Pd-1 Monoclonal Antibodies in Glioblastoma

MA04.02 Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-Pd-1

Efficacy of Chemotherapy or Chemo-Anti-Pd-1 Combination After Failed Anti-Pd-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Series From Lysa Centers

P3.04-25 EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC With PD-L1 <50%

Can IDO Activity Predict Primary Resistance to Anti-Pd-1 Treatment in NSCLC?

P3.04-24 EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC With PD-L1 ≥50%, a Phase 3 Study